Final results of the global and Asia cohorts of KAMILLA, a phase IIIB safety trial of trastuzumab emtansine in patients with HER2-positive advanced breast cancer

R Wuerstlein, P Ellis, F Montemurro, A Antón Torres, S Delaloge, Q Zhang, X Wang, S Wang, Z Shao, H Li, A Rachman, M Vongsaisuwon, H Liu, S Fear, C Peña-Murillo, C Barrios, R Wuerstlein, P Ellis, F Montemurro, A Antón Torres, S Delaloge, Q Zhang, X Wang, S Wang, Z Shao, H Li, A Rachman, M Vongsaisuwon, H Liu, S Fear, C Peña-Murillo, C Barrios

Abstract

Background: KAMILLA is a single-arm safety study of trastuzumab emtansine (T-DM1) in patients with human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer (BC; NCT01702571). We report the final analysis of cohort 2 (Asia) within the context of published cohort 1 (Global) findings.

Methods: Patients had HER2-positive, locally advanced, or metastatic BC progressing after chemotherapy and anti-HER2 therapy or ≤6 months after adjuvant therapy. The primary objective was to further evaluate T-DM1 (3.6 mg/kg, administered intravenously every 3 weeks) safety/tolerability, including the following adverse events of primary interest (AEPIs): grade ≥3 AEPIs (hepatic events, allergic reactions, thrombocytopenia, hemorrhage events), all grade ≥3 treatment-related AEs, and all-grade pneumonitis.

Results: KAMILLA enrolled 2185 patients (cohort 1, n = 2003; cohort 2, n = 182) as of 31 July 2019. Of these, 2002 and 181 per cohort were treated and included in the safety population. Approximately 70% of patients had two or more previous treatment lines in the metastatic setting. Median T-DM1 exposure was 5.6 and 5.0 months per cohort; median follow-up was 20.6 and 15.1 months. The overall AEPI rate was higher in cohort 2 (93/181; 51.4%) versus cohort 1 (462/2002; 23.1%), mostly driven by a higher grade ≥3 thrombocytopenia rate in cohort 2. In cohort 2, grade ≥3 thrombocytopenia was not associated with grade ≥3 hemorrhagic events and most (128/138) fully resolved. Grade ≥3 treatment-related AEPI rates were 18.4% (cohort 1) and 48.6% (cohort 2), the latter mainly due to thrombocytopenia. Any-grade pneumonitis rates were 1.0% and 2.2%. No new safety signals were identified. Median (95% confidence interval) progression-free survival was 6.8 months (5.8-7.6 months) and 5.7 months (5.5-7.0 months) in cohorts 1 and 2, respectively; median overall survival was 27.2 months (25.5-28.7 months) and 29.5 months (21.1 months to non-estimable). In both cohorts, median progression-free survival and overall survival decreased with increasing prior therapy lines.

Conclusions: Cohort 2 results aligned with previous findings in Asian patients, supporting the manageable safety profile and use of T-DM1 in advanced BC.

Keywords: Asia; HER2-positive metastatic breast cancer; KAMILLA; safety; trastuzumab emtansine (TDM-1).

Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.

Figures

Figure 1
Figure 1
Patient disposition. (A) Cohort 1—globala; (B) cohort 2—Asia. AE, adverse event; ITT, intent-to-treat. aPatient disposition diagram for cohort 1 previously published in Montemurro et al., Eur J Cancer. 2019;109:92–102.
Figure 2
Figure 2
Progression-free survival. (A) Cohort 1—global; (B) cohort 2—Asia. +Censored. Intent-to-treat population (cohort 1, n = 2003; cohort 2, n = 182). CI, confidence interval.
Figure 3
Figure 3
Overall survival. (A) Cohort 1—global; (B) cohort 2—Asia. +Censored. Intent-to-treat population (cohort 1, n = 2003; cohort 2, n = 182). CI, confidence interval, NE, non-estimable.

References

    1. Kadcyla® prescribing information: Genentech, Inc. 2019. Available at.
    1. Kadcyla® summary of product characteristics. Available at.
    1. Barok M., Joensuu H., Isola J. Trastuzumab emtansine: mechanisms of action and drug resistance. Breast Cancer Res. 2014;16:209.
    1. Verma S., Miles D., Gianni L., et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367:1783–1791.
    1. Krop I.E., Kim S.B., González-Martín A., et al. Trastuzumab emtansine versus treatment of physician’s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomized open-label, phase 3 trial. Lancet Oncol. 2014;15:689–699.
    1. Krop I.E., Kim S.B., Martin A.G., et al. Trastuzumab emtansine versus treatment of physician’s choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial. Lancet Oncol. 2017;18:743–754.
    1. Vici P., Pizzuti L., Michelotti A., et al. A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience. Oncotarget. 2017;8:56921–56931.
    1. Conte B., Fabi A., Poggio F., et al. T-DM1 efficacy in patients with HER2-positive metastatic breast cancer progressing after a taxane plus pertuzumab and trastuzumab: an Italian multicenter observational study. Clin Breast Cancer. 2020;20:e181–e187.
    1. Bahçeci A., Paydaş S., Ak N., et al. Efficacy and safety of trastuzumab emtansine in HER2 positive metastatic breast cancer: real-world experience. Cancer Invest. 2021;39:473–481.
    1. Hardy-Werbin M., Quiroga V., Cirauqui B., et al. Real-world data on T-DM1 efficacy – results of a single-center retrospective study of HER2-positive breast cancer patients. Sci Rep. 2019;9:12760.
    1. Montemurro F., Ellis P., Anton A., et al. Safety of trastuzumab emtansine (T-DM1) in patients with HER2-positive advanced breast cancer: primary results from the KAMILLA study cohort 1. Eur J Cancer. 2019;109:92–102.
    1. Dieras V., Harbeck N., Budd G.T., et al. Trastuzumab emtansine in human epidermal growth factor receptor 2-positive metastatic breast cancer: an integrated safety analysis. J Clin Oncol. 2014;32:2750–2757.
    1. National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), v4.0. Available at.
    1. Im S., Park I., Sohn J.H., et al. Trastuzumab emtansine (T-DM1) in Asian patients with previously treated HER2-positive locally advanced (LA) or metastatic breast cancer (MBC): data from the phase III EMILIA study. Ann Oncol. 2021;32:S457–S515.
    1. Modi N., Sorich M.J., Rowland A., et al. Predicting thrombocytopenia in patients with breast cancer treated with ado-trastuzumab emtansine. Clin Breast Cancer. 2020;20:e220–e228.
    1. Hackshaw M.D., Danysh H.E., Singh J., et al. Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2020;183:23–39.
    1. Modi S., Saura C., Yamashita T., et al. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N Engl J Med. 2020;382:610–621.
    1. von Minckwitz G., Huang C.S., Mano M.S., et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380:617–628.
    1. Cortés J., Kim S., Chung W., et al. LBA1; 2021. Trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): results of the randomized phase III DESTINY-Breast03 study. Presented at the European Society for Medical Oncology conference.
    1. Montemurro F., Delaloge S., Barrios C.H., et al. Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial. Ann Oncol. 2020;31:1350–1358.
    1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer Guidelines V.8.2021. © National Comprehensive Cancer Network, Inc. 2021. All rights reserved. Accessed February 17, 2022. To view the most recent and complete version of the guideline, go online to . NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
    1. Cardoso F., Paluch-Shimon S., Senkus E., et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) Ann Oncol. 2020;31:1623–1649.
    1. Thill M., Friedrich M., Kolberg-Liedtke C., et al. AGO recommendations for the diagnosis and treatment of patients with locally advanced and metastatic breast cancer: update 2021. Breast Care (Basel) 2021;16:228–235.
    1. Tykerb® prescribing information: Novartis Pharmaceuticals Corporation. 2018. Available at.
    1. Nerlynx® prescribing information: Puma Biotechology, Inc. 2020. Available at.
    1. TukysaTM prescribing information: Seattle Genetics, Inc. 2020. Available at.
    1. Saura C., Oliveira M., Feng Y.H., et al. Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with ≥2 HER2-directed regimens: phase III NALA trial. J Clin Oncol. 2020;38:3138–3149.
    1. Murthy R.K., Loi S., Okines A., et al. Tucatinib, trastuzumab, and caepcitabine for HER2-positive metastatic breast cancer. N Engl J Med. 2020;13:597–609.
    1. Borges V.F., Ferrario C., Aucoin N., et al. Tucatinib combined with ado-trastuzumab emtansine in advanced ERBB2/HER2-positive metastatic breast cancer: a phase 1b clinical trial. JAMA Oncol. 2018;4:1214–1220.
    1. Blair H.A. Pyrotinib: first global approval. Drugs. 2018;78:1751–1755.
    1. Ma F., Ouyang Q., Li W., et al. Pyrotinib or lapatinib combined with capecitabine in HER2-positive metastatic breast cancer with prior taxanes, anthracyclines, and /or trastuzumab: a randomized/phase II study. J Clin Oncol. 2019;37:2610–2619.
    1. Enhertu® prescribing information: Daiichi Sankyo, Inc. 2021. Available at.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa